SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01830244

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer

The aim of this project is to evaluate tailored primary systemic therapy with sequential nab paclitaxel and epirubicin and cyclophosphamide in early breast cancer. This study will be an open label phase II clinical trial. The hypothesis is that tailored neoadjuvant chemotherapy with sequential nab paclitaxel and epirubicin and cyclophosphamide is feasible and achieves high response rates. It is proposed that 60 patients will be enrolled in this study including 40 patients which are likely to have chemotherapy sensitive tumors and 20 patients who have ER positive tumors and are more likely to respond to hormonal treatment as an exploratory cohort. The target population is women with early breast cancer who are eligible for primary systemic therapy. The overall response rate in the breast will be measured. Secondary endpoints will include response rates in axillary lymph nodes, safety and tolerability and the rate of breast conservation. Participants will have a blood test to determine a specific genotype status that may help in predicting sensitivity to chemotherapy. This genotype test result is exploratory and will not influence selection of therapy for participants. Patients will also be given the option of having he their tumour tissues used in laboratory studies involving isolating cancer initiating cells from the tumor to subsequently generate breast cancer models in the laboratory and using aptamers (chemical antibodies) to target tumours.

NCT01830244 Breast Cancer
MeSH:Breast Neoplasms
HPO:Breast carcinoma Neoplasm of the breast

1 Interventions

Name: Nab-Paclitaxel

Description: Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
Type: Drug
Group Labels: 1

Nab-Paclitaxel 125mg/m2

Primary Outcomes

Description: Pathological complete response defined as breast only, ypT0/ ypTis regardless of nodal status

Measure: Pathological complete response in the breast

Time: 24 weeks (time window + 4 weeks)

Secondary Outcomes

Description: Pathologic assessment

Measure: Pathologic Response rate in breast and axillary lymph nodes

Time: 24 weeks (time window + 4 weeks)

Description: Pathologic assessment

Measure: Rate of pathologic complete response and near complete response in the breast combined

Time: 24 weeks (time window + 4 weeks)

Measure: Breast conservation rate

Time: 24 weeks (time window + 4 weeks)

Measure: Progression Free Survival

Time: 5 years

Description: Safety will be measured using NCI Common Toxicity Criteria for Adverse Effects version 4.0

Measure: Safety and tolerability

Time: During treatment (24 weeks)

Other Outcomes

Measure: NQ01*2 genotype (P187S) status

Time: Baseline

Purpose: Treatment

Allocation: N/A

Single Group Assignment

There is one SNP


1 rs1800566

A homozygous common missense variant (NQO1*2, rs1800566(T), NM_000903.2:c.558C4T) that disables NQO1 strongly has been shown to predicts poor survival among two independent series of women with breast cancer, an effect particularly evident after anthracycline based adjuvant chemotherapy with epirubicin[44].

HPO Nodes